Experimental Hematology
Volume 36, Issue 11 , Pages 1403-1416 , November 2008

Final checkup of neoplastic DNA replication: Evidence for failure in decision-making at the mitotic cell cycle checkpoint G1/S

  • Gregor Prindull

      Affiliations

    • Corresponding Author InformationOffprint requests to: Gregor Prindull, M.D., University of Göttingen, Department of Pediatrics, Robert-Koch-Strasse 4, Göttingen, 37075, Germany

Received 18 June 2008 ,Revised 29 July 2008 ,Accepted 29 July 2008.

References 

  1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111
  2. Haan de G, Nijhof W, Zant van G. Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: correlation between lifespan and cycling activity. Blood. 1997;89:1543–1550
  3. Chen J, Astle CM, Harrison DE. Development and aging of primitive hematopoietic stem cells in BALB/cBy mice. Exp Hematol. 1999;27:928–935
  4. Marley SB, Lewis JL, Davidson RJ, et al. Evidence for a continuous decline in hematopoietic cell function from birth: application to evaluating bone marrow failure in children. Br J Haematol. 1999;106:162–166
  5. Zant van G, Liang Y. The role of stem cells in aging. Exp Hematol. 2003;31:659–672
  6. Liang Y, Zant van G, Szilvassy SJ. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood. 2005;106:1479–1487
  7. Xing Z, Ryan MA, Daria D, et al. Increased hematopoietic stem cell mobilization in aged mice. Blood. 2006;108:2190–2197
  8. Colvin GA, Dooner MS, Dooner GJ, et al. Stem cell continuum: directed differentiation hotspots. Exp Hematol. 2007;35:96–107
  9. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet. 2002;3:662–673
  10. Prindull G, Zipori D. Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. Blood. 2004;103:2892–2899
  11. Jepsen K, Rosenfeld MG. Biological roles and mechanistic actions of co-repressor complexes. J Cell Sci. 2002;115:689–698
  12. Kel-Margoulis OV, Tschekmenev D, Kel AE, et al. Composition-sensitive analysis of the human genome for regulatory signals. In Silico Biol. 2003;3:145–171
  13. Suzuki Y, Yamashita R, Shirota M, et al. Large-scale collection and characterization of promotors of human and mouse genes. In Silico Biol. 2004;4:429–444
  14. Campbell KHS, Loi P, Otaegui PJ, Wilmut I. Cell cycle co-ordination in embryo cloning by nuclear transfer. Rev Reprod. 1996;1:40–46
  15. Humpherys D, Eggan K, Akutsu H, et al. Epigenetic instability in ES cells and cloned mice. Science. 2001;293:95–97
  16. Wilmut I, Beaujean N, de Sousa PA, et al. Somatic cell nuclear transfer. Nature. 2002;419:583–586
  17. Tamada H, Kikyo N. Nuclear reprogramming in mammalian somatic cell nuclear cloning. Cytogenet Genome Res. 2004;105:285–291
  18. Dean W, Santos F, Reik W. Epigenetic reprogramming in early mammalian development and following somatic nuclear transfer. Semin Cell Develop Biol. 2003;14:93–100
  19. Niemann H, Tian XC, King WA, Lee RSF. Epigenetic reprogramming in embryonic and foetal development upon somatic cell nuclear transfer cloning. Reproduction. 2008;135:151–163
  20. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3:895–902
  21. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–692
  22. Hong D, Gupta R, Ancliff P, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science. 2008;319(5861):336–339
  23. Prindull G. Hypothesis: cell plasticity, linking embryonal stem cells to adult stem cell reservoirs and metastatic cancer cells?. Exp Hematol. 2005;33:738–746
  24. Knudson AG. Mutation and cancer. Proc Natl Acad Sci U S A. 1971;68:820–823
  25. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006;7:21–33
  26. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–649
  27. Dreesen O, Brivanlou AH. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev. 2007;3:7–17
  28. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457–463
  29. Edelman EJ, Guinney J, Chi JT, Febbo PG, Mukherjee S. Modeling cancer progression via pathway dependencies. PloS Comput Biol. 2008;4(2):e28
  30. Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A. 2005;102:9194–9199
  31. Bagnara GP, Bonsi L, Strippoli P, et al. Hematopoiesis in healthy old people and centenarians: well-maintained responsiveness of CD34+ cells to hematopoietic growth factors and remodeling of cytokine network. J Gerontol Biol Sci. 2000;55A:B61–B70
  32. Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer. 1999;35:531–539
  33. Lowe SW, Cepero E, Evan G. Intrinsic tumor suppression. Nature. 2004;432:307–315
  34. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005;37:961–976
  35. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol. 2007;19:238–245
  36. Shiloh Y. ATM and related protein kinases: safegurading genome integrity. Nat Rev Cancer. 2003;3:155–168
  37. Lieb JD, Beck S, Bulyk ML, et al. Applying whole-genome studies of epigenetic regulation to study human disease. Cytogenet Genome Res. 2006;114:1–15
  38. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature Genet Suppl. 2003;33:245–254
  39. Cutfield WS, Hofman PL, Mitchell M, Morison IM. Could epigenetics play a role in the developmental origins of health and disease?. Pediatr Res. 2007;61:68R–75R
  40. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science. 2001;293:1089–1093
  41. Hasty P, Campisi J, Hoeijmakers J, Steeg van H, Vijg J. Aging and genome maintenance: lessons from the mouse?. Science. 2003;299:1355–1359
  42. Barker DJ. The fetal and infant origins of adult disease. BMJ. 1990;301:1111
  43. Crews D, McLachlan JA. Epigenetics, evolution, endocrine disruption, health, and disease. Endocrinology. 2006;147(Suppl):S4–S10
  44. Coe CL, Lubach GR, Shirtcliff EA. Maternal stress during pregnancy predisposes for iron deficiency in infant monkeys impacting innate immunity. Pediatr Res. 2007;61:520–524
  45. Lanzuolo C, Orlando V. The function of the epigenome in cell reprogramming. Cell Mol Life Sci. 2007;64:1043–1062
  46. McEvoy TG, Ashworth CJ, Rooke JA, Sinclair KD. Consequences of manipulating gametes and embryos of ruminant species. Reprod Suppl. 2003;61:167–182
  47. Gao S, Latham KE. Maternal and environmental factors in early cloned embryo development. Cytogenet Genome Res. 2004;105:279–284
  48. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005;102:10604–10609
  49. Wong AHC, Gottesman IL, Petronis A. Phenotypic differences in genetically identical organisms: the epigenetic perspective. Human Mol Genet. 2005;14:R11–R18
  50. Petronis A. Epigenetics and twins: three variations on the theme. Trends Genet. 2006;22:347–350
  51. Bohr VA. DNA damage and its processing. Relation to human disease. J Inherit Metab Dis. 2002;25:215–222
  52. Berardi P, Russell M, El-Osta A, Riabowol K. Functional links between transcription, DNA repair and apoptosis. Cell Mol Life Sci. 2004;61:2173–2180
  53. Boer de J, Andressoo JO, Wit de J, et al. Premature aging in mice deficient in DNA repair and transcription. Science. 2002;296:1276–1279
  54. Syljuasen RG, Jensen S, Bartek J, Lukas J. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polio-like kinase 1 kinases. Cancer Res. 2006;66:10253–10257
  55. Hutter G, Scheubner M, Zimmermann Y, et al. Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantel cell lymphoma. Genes Chromosomes Cancer. 2006;45:203–210
  56. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis. 2007;22:91–103
  57. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early pathway addiction. Nature Rev Cancer. 2006;6:107–116
  58. Jones PA. Overview of cancer epigenetics. Semin Hematol. 2005;42(Suppl):S3–S8
  59. Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39:157–158
  60. Ringrose L, Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet. 2004;38:413–443
  61. Lee TI, Jenner RG, Boyer LA, et al. Control of developmental regulators by polycomb in human embryonic stem cells. Cell. 2006;125:301–313
  62. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006;20:1123–1136
  63. Janzen V, Forkert R, Fleming HE, et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature. 2006;443:421–426
  64. Burdon T, Smith A, Savatier P. Signalling, cell cycle and pluripotency in embryonal stem cells. Trends Cell Biol. 2002;12:432–438
  65. Hardy K, Handyside AH, Winston RML. The human blastocyst: cell number, death and allocation during late preimplantation development in vitro. Development. 1989;107:597–604
  66. Jurisicova A, Rogers I, Fasciani A, Casper RF, Varmuza S. Effect of maternal age and conditions of fertilization on programmed cell death during murine preimplantation embryo development. Mol Hum Reprod. 1998;4:139–145
  67. Draper JS, Moore HD, Ruban LN, Gokhale PJ, Andrews PW. Culture and characterization of human embryonic stem cells. Stem Cells Dev. 2004;13:325–336
  68. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416:552–556
  69. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003;299:1753–1755
  70. Mantel C, Guo Y, Lee MR, et al. Checkpoint-apoptosis uncoupling in human and mouse embryonic stem cells: a source of karyotypic instability. Blood. 2007;109:4518–4527
  71. Yu H. Regulation of APC-Cdc20 by the spindle checkpoint. Curr Opin Cell Biol. 2002;14:706–714
  72. Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene. 2004;23:2016–2927
  73. Kops GJPL, Foltz DR, Cleveland DW. Lethality to human cancer cells through masssive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A. 2004;101:8699–8704
  74. Boyapati A, Yan M, Peterson LF, Biggs JR, LeBeau MM, Zhang DE. A leukemic fusion protein attenuates the spindle checkpoint and promotes aneuploidy. Blood. 2007;109:3963–3971
  75. Wiemels JL, Xiao Z, Buffler PA, et al. In utero origin of t(8;21) AML1-Eto translocations in childhood acute myeloid leukemia. Blood. 2002;99:3801–3805
  76. Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. Blood. 2003;102:2321–2333
  77. Scintu M, Vitale R, Prencipe M, et al. Genomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinoma. Cancer Lett. 2007;254:298–307
  78. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16:6–21
  79. Kirkland MA, Quesenberry PJ, Roeder I. discrete stem cells: subsets or a continuum? [letter]. Blood. 2006;108:3949
  80. Paro R. Propagating memory of transcriptional states. Trends Genet. 1995;11:295–297
  81. Issa JP. Age-related epigenetic changes and the immune system. Clin Immunol. 2003;109:103–108
  82. Shen X, Xiao H, Ranallo R, Wu WH, Wu C. Modulation of ATP-dependent chromatin-remodeling complexes by inositol polyphosphates. Science. 2003;299:112–114
  83. Ling JQ, Hoffman AR. Epigenetics of long-range chromatin interactions. Pediatr Res. 2007;61:11R–16R
  84. Surani MA. Reprogramming of genome function through epigenetic inheritance. Nature. 2001;414:122–128
  85. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122:947–956
  86. Cavalli G. Chromatin as a eukaryotic template of genetic information. Curr Opin Cell Biol. 2002;14:269–278
  87. Simon JA, Tamkun JW. Programming off and on states in chromatin: mechanisms of polycomb and thrithorax group complexes. Curr Opin Genet Dev. 2002;12:210–218
  88. Wolffe AP, Guschin D. Review: chromatin structural features and targets that regulate transcription. J Struct Biol. 2000;129:102–122
  89. Lund AH, Lohuizen van M. Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol. 2004;16:239–246
  90. Erhardt S, Lyko F, Ainscough JFX, Surani MA, Paro R. Polycomb-group proteins are involved in silencing processes caused by a transgenic element from the murine imprinted H19/Igf2 region in Drosophila. Dev Genes Evol. 2003;213:336–344
  91. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002;3:11–20
  92. Müller H, Bracken AP, Vernell R, et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 2001;15:267–285
  93. Henikoff S, Ahmad K. Assembly of variant histones into chromatin. Ann Rev Cell Dev Biol. 2005;21:133–153
  94. Hannon GJ. RNA interference. Nature. 2002;418:244–251
  95. Tomasi TB, Magner WJ, Khan ANH. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother. 2006;55:1159–1184
  96. Kamminga LM, Bystrykh LV, Boer de A, et al. The polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood. 2006;107:2170–2179
  97. Reynolds PA, Sigaroudinia M, Zardo G, et al. Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem. 2006;281:24790–24802
  98. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene. 2004;23:5759–5769
  99. Pirrotta V. Chromatin complexes regulating gene expression in Drosophila. Curr Opin Genet Dev. 1995;5:466–472
  100. Viré E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439:871–874
  101. Voncken JW, Schweizer D, Aagaard L, Sattler L, Jantsch MF, Lohuizen van M. Chromatin-association of the Polycomb group protein BMI1 is cell cycle-regulated and correlates with its phosphorylation status. J Cell Sci. 1999;112:4627–4639
  102. Caldas C, Aparicio S. Cell memory and cancer—the story of the trithorax and polycomb group genes. Cancer Metastasis Rev. 1999;18:313–329
  103. Piotrowski A. Genes Chromosomes Cancers. 2006;45:656–667
  104. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukemia stem cell initiated by MLL-AF9. Nature. 2006;442:818–822
  105. Valk-Lingbeek ME, Bruggeman SWM, Lohuizen van M. Stem cells and cancer: the polycomb connection. Cell. 2004;118:409–418
  106. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–1261
  107. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A. 1992;89:10114–10118
  108. Khoo CM, Carrasco DR, Bodenberg MW, Paik JH, DePinho RA. Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomere-deficient mouse. Proc Natl Acad Sci U S A. 2007;104:3931–3936
  109. Campisi J, Kim S, Lim CS, Rubio M. Cellular senescence, cancer and aging: the telomere connection. Exp Gerontol. 2001;36:1619–1637
  110. Hug N, Linger J. Telomere length homeostasis. Chromosoma. 2006;115:413–425
  111. Jacob NK, Lescasse RL, Linger BR, Price CM. Tetrahymena POT1a regulates telomere length and prevents activation of a cell cycle checkpoint. Mol Cell Biol. 2007;27:1592–1601
  112. Glover L, Alsford S, Beattie C, Horn D. Deletion of a trypanosome telomere leads to loss of silencing and progressive loss of terminal DNA in the absence of cell cycle arrest. Nucl Acids Res. 2007;35:872–880
  113. Itahana K, Campisi J, Dimri G. Mechanisms of cellular senescence in human and mouse cells. Biogerontology. 2004;5:1–10
  114. Johnson FB, Sinclair DA, Guarente L. Molecular biology of aging. Cell. 1999;96:291–302
  115. Multani AS, Chang S. WRN at telomeres: implications for aging and cancer. J Cell Sci. 2007;120:713–721
  116. Lange de T, Jacks T. For better or worse? Telomerase inhibition and cancer. Cell. 1999;98:273–275
  117. Caslini C, Hess JL. MLL modulates telomere length in mammalian cells. Blood. 2006;108(11, part 1):626a, Abstract 2209
  118. Yui J, Chiu CP, Lansdorp PM. Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood. 1998;91:3255–3262
  119. Serakinci N, Hoare SF, Kassem M, Atkinson SP, Keith WN. Telomerase promotor reprogramming and interaction with general transcription factors in the human mesenchymal stem cell. Regen Med. 2006;1:125–131
  120. Beliveau A, Bassett E, Lo AT, et al. p53-dependent integration of telomere and growth factor deprivation signals. Proc Natl Acad Sci U S A. 2007;104:4431–4436
  121. Beauséjour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003;22:4212–4222
  122. Holt SE, Glinsky VV, Ivanova AB, Glinsky GV. Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinog. 1999;25:241–248
  123. Maser RS, Wong KK, Sahin E, et al. DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse. Mol Cel Biol. 2007;27:2253–2265
  124. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomerase loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell. 1999;97:527–538
  125. Nguyen DC, Crowe DL. Intact functional domains of the retinoblastoma gene product (pRb) are required for downregulation of telomerase activity. Biochim Biophys Acta. 1999;1445:207–215
  126. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194–198
  127. Reddel RR. The role of senescence and immortalization in carcinogenesis. Carcinogenesis. 2000;21:477–484
  128. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet. 2001;28:155–159
  129. Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, and cancer. J Clin Invest. 2004;113:160–168
  130. González-Suárez E, Samper E, Flores JM, Blasco MA. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Genet. 2000;26:114–117
  131. Ji HJ, Rha SY, Jeung HC, Yang SH, An SW, Chung HC. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Breast Cancer Res Treat. 2005;93:227–236
  132. Guittat L, Alberti P, Gomez D, et al. Targeting human telomerase for cancer therapeutics. Cytotechnology. 2004;45:75–90
  133. Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. J Urol. 2004;171:1934–1938
  134. Datta A, Bellon M, Sinha-Datta U, et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood. 2006;108:1021–1029
  135. Kim GD, Ni J, Kelesoglu N, Roberts RJ, Pradhan S. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J. 2002;21:4183–4195
  136. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science. 2001;293:1068–1070
  137. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998;12:2245–2262
  138. Rashidian J, Iyirhiaro GO, Park DS. Cell cycle machinery and stroke. Biochim Biophys Acta. 2007;1772:484–493
  139. Bartek J, Lukas J. Order from destruction. Science. 2001;294:66–67
  140. Devaskar SU, Raychaudhuri S. Epigenetics—a science of heritable biological adaptation. Pediatr Res. 2007;61:1R–4R
  141. Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. Curr Opin Cell Biol. 2003;15:172–183
  142. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41–45
  143. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074–1080
  144. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte FJ. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci U S A. 2003;983:84–100
  145. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol. 2004;14:R546–R551
  146. Swat M, Kel A, Herzel H. Bifurcation analysis of the regulatory modules of the mammalian G1/S transition. Bioinformatics. 2004;20:1506–1511
  147. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–870
  148. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–1512
  149. Sudarsanam P, Winston F. The Swi/Snf family: nucleosome-remodeling complexes and transcriptional control. Trends Genet. 2000;16:345–351
  150. Angelov D, Molla A, Perche PY, et al. The histone variant macroH2A interferes with transcription factor binding and SWI/SNF nucleosome remodeling. Mol Cell. 2003;11:1033–1041
  151. Kornberg RD. The eukaryotic gene transcription machinery. Biol Chem. 2001;382:1103–1107
  152. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005;23:3971–3993
  153. Saunders A, Core LJ, Lis JT. Breaking barriers to transcription elongation. Mol Cell Biol. 2006;7:557–567
  154. Liu H, Takeda S, Cheng EHY, Hsieh JD. Biphasic MLL takes helm at cell cycle control. Cell Cycle. 2008;7:428–435
  155. Sotillo E, Garriga J, Kurimchak A, Grana X. Cyclin E and SV40 Small t Antigen cooperates to bypass quiescence and contribute to transformation by activating CDK2 in human fibroblasts. J Biol Chem. 2008;283:11280–11292
  156. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev. 2003;13:77–83
  157. Stein GH, Drullinger LF, Soulard A, Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol. 1999;19:2109–2117
  158. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A. 1996;93:13742–13747
  159. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol. 2001;2:731–737
  160. Bates S, Phillips AC, Clark PA, et al. p14ARF links the tumour suppressors RB and p53. Nature. 1998;395:124–125
  161. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993–1000
  162. Rowland BD, Denissov SG, Douma S, Stunnenberg HG, Bernards R, Peeper DS. E2F transcriptional repressor complexes are critical downstream targets of p19ARF/p53-induced proliferative arrest. Cancer Cell. 2002;2:55–65
  163. Carnero A, Hudson JD, Price CM, Beach DH. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol. 2000;2:148–155
  164. Gonzalez-Paz N, Chng WJ, McClure RF, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood. 2007;109:1228–1232
  165. Dib A, Barlogie B, Shaughnessy JD, Kuehl WM. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood. 2007;109:1337–1338
  166. Hitomi T, Matsuzaki Y, Yasuda S, et al. Oct-1 is involved in the transcriptional repression of the p15INK4b gene. FEBS Lett. 2007;581:1087–1092
  167. Golubnitschaja O. Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases. Amino Acids. 2007;32:359–371
  168. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907–913
  169. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–1677
  170. Azechi H, Nishida N, Fukuda Y, et al. Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology. 2001;60:346–354
  171. Chen S, Chen L, Le NT, et al. Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors. Bioorgan Med Chem Lett. 2007;17:2134–2138
  172. Grillo M, Bott MJ, Khandke N, et al. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat. 2006;95:185–194
  173. Joshi KS, Rathos MJ, Joshi RD, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007;6:918–925
  174. Tagoh H, Melnik S, Lefevre P, Chong S, Riggs AD, Bonifer C. Dynamic reorganization of chromatin structure and selective DNA demethylation prior to stable enhancer complex formation during differentiation of primary hematopoietic cells in vitro. Blood. 2004;103:2950–2955
  175. Ezhevsky SA, Nagahara H, Vocero-Akbani AM, Gius DR, Wei MC, Dowdy SF. Hypo-phosphorylation of the retinoblastoma protein (pRB) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci U S A. 1997;94:10699–10704
  176. Knudsen KE, Weber E, Arden KC, Cavenee WK, Feramisco JR, Knudsen ES. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene. 1999;18:5239–5245
  177. Lim IK. TIS21/BTG2/PC3 as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule. J Cancer Res Clin Oncol. 2006;132:417–426
  178. Lwin T, Hazlehurst LA, Dessureault S, et al. Cell adhesion induces p27Kip1-associated cell cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 2007;110:1631–1638
  179. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–707
  180. Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113:703–716
  181. Imai MA, Oda Y, Oda M, Nakanishi I, Kawahara E. Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma. J Cancer Res Clin Oncol. 2004;130:320–326
  182. Vousden KH. p53: death star. Cell. 2000;103:691–694
  183. Fan G, Ma X, Wong PY, Rodrigues CMP, Steer CJ. p53 dephosphorylation and p21Cip/Waf1 translocation correlate with caspase-3 activation in TGF-β1-induced apoptosis of HuH-7 cells. Apoptosis. 2004;9:211–221
  184. Khan SH, Moritsugu J, Wahl GM. Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc Natl Acad Sci U S A. 2000;97:3266–3271
  185. Varela I, Cadinanos J, Pendás AM, et al. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature. 2005;437:564–568
  186. Ries S, Biederer C, Woods D, et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell. 2000;103:321–330
  187. Dumble M, Moore L, Chambers SM, et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood. 2007;109:1736–1742
  188. Peterson EJ, Bögler O, Taylor SM. p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Res. 2003;63:6579–6582
  189. Ren B, Cam H, Takahashi Y, et al. E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev. 2002;16:245–256
  190. Rayman JB, Takahashi Y, Indjeian VB, et al. E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev. 2002;16:933–947
  191. Stanelle J, Stiewe T, Theseling CC, Peter M, Pützer BM. Gene expression changes in response to E2F1 activation. Nucleic Acid Res. 2002;30:1859–1867
  192. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature. 1998;395:125–126
  193. Krishnamurthy J, Ramsey MR, Ligon KL, et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature. 2006;443:453–457
  194. Molofsky AV, Slutsky SG, Joseph NM, et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during aging. Nature. 2006;443:448–452
  195. Frolov MV, Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci. 2004;117:2173–2181
  196. Bannister AJ, Schneider R, Kouzarides T. Histone methylation: dynamic or static?. Cell. 2002;109:801–806
  197. Rea S, Eisenhaber F, O'Carroll D, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature. 2000;406:593–599
  198. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3:253–266
  199. Lachner M, Jenuwein T. The many faces of histone lysine methylation. Curr Opin Cell Biol. 2002;14:286–298
  200. Grewal SIS, Elgin SCR. Heterochromatin: new possibilities for the inheritance of structure. Curr Opin Genet Dev. 2002;12:178–187
  201. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell. 2003;3:89–95
  202. Hendzel MJ, Wei Y, Mancini MA, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentrometric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997;106:348–360
  203. Hake SB, Xiao A, Allis CD. Linking the epigenetic “language” of covalent histone modifications to cancer. Br J Cancer. 2004;90:761–769
  204. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24:1770–1783
  205. Senese S, Zaragoza K, Minardi S, et al. Role for histone deacetylase 1 in human tumor proliferation. Mol Cell Biol. 2007;27:4784–4795
  206. Schneider R, Bannister AJ, Kouzarides T. Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci. 2002;27:396–402
  207. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev. 2002;12:198–209
  208. Lee JH, Hart SRL, Skalnik DG. Histone deacetylase activity is required for embryonic stem cell differentiation. Genesis. 2004;38:32–38
  209. Chang KT, Min KT. Regulation of lifespan by histone deacetylase. Ageing Res Rev. 2002;1:313–326
  210. Görisch SM, Wachsmuth M, Tóth KF, Lichter P, Rippe K. Histone acetylation increases chromatin accessibility. J Cell Sci. 2005;118:5825–5834
  211. Pandita TK, Hunt CR, Sharma GG, Yang Q. Regulation of telomere movement by telomere chromatin structure. Cell Mol Life Sci. 2007;64:131–138
  212. Godfrey KM, Lillycrop KA, Burdge GC, Gluckman PD, Hanson MA. Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease. Pediatr Res. 2007;61:5R–10R
  213. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys 16 and trimethylation at Lys 20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37:391–400
  214. Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates cancer silenced genes without loss of promotor DNA hypermethylation. PLoS Genet. 2006;2:e40
  215. Li H, Wu X. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promotor in human cervical cancer cells. Biochem Biophys Res Com. 2004;324:860–867
  216. Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat. 2007;10:162–181
  217. Lindemann RK, Gabrielli B, Johnstone RW. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle. 2004;3:779–788
  218. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007;109:2781–2790
  219. Vlasáková J, Nováková Z, Rossmeislová L, Kahle M, Hozák P, Hodný Z. Histone deacetylase inhibitors suppress IFNα–induced up-regulation of promyelocytic leukemia protein. Blood. 2007;109:1373–1380
  220. Florenes VA, Skrede M, Jorgensen K, Nesland JM. Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival. Melanoma Res. 2004;14:173–181
  221. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 2005;11:71–76
  222. Zhang K, Williams KE, Huang L, et al. Histone acetylation and deacetylation: identification of acetylation and methylation sites of hela histone H4 by mass spectrometry. Mol Cell Proteomics. 2002;1:500–508
  223. Horn PJ, Peterson CL. Heterochromatin assembly: a new twist on an old model. Chromosome Res. 2006;14:83–94
  224. Yang XJ. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 2004;32:959–976
  225. Kitabayashi I, Aikawa Y, Yokoyama A, et al. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia. 2001;15:89–94
  226. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 2001;15:2343–2360
  227. Fischle W, Wang Y, Jacobs SA, Kim Y, Allis CD, Khorasanizadeh S. Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. Genes Dev. 2003;17:1870–1881
  228. Crawford BD, Hess JL. MLL core components give the green light to histone methylation. ACS Chem Biol. 2006;1:495–498
  229. Yokoyama A, Wang Z, Wysocka J, et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol. 2004;24:5639–5649
  230. Lee JH, Skalnik DG. CpG-binding protein (CXXC finger protein 1) is a component of the mammalian Set 1 histone H3-Lys4 methyltransferase complex, the analogue of the yeast Set1/COMPASS complex. J Biol Chem. 2005;280:41725–41731
  231. Dou Y, Milne TA, Tackett AJ, et al. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell. 2005;121:873–885
  232. Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A. 2005;102:749–754
  233. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A. 2002;99:3740–3745
  234. Fröhling S, Scholl C, Bansal D, Huntly JP. HOX gene regulation in acute myeloid leukemia. Cell Cycle. 2007;6:2241–2245
  235. Ansari KI, Mishra BP, Mandal SS. Human CpG binding protein interacts with MLL1, MLL2 and hSet1 and regulates Hox gene expression. Biochim Biophys Acta. 2008;1779:66–73
  236. Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 2007;67:7275–7283
  237. Daser A, Rabbitts TH. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev. 2004;18:965–974
  238. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promotors. Nat Genet. 2000;25:338–342
  239. Bachman KE, Rountree MR, Baylin SB. Dnmt3a and Dnmt3b are transcription repressors that exhibit unique locatization properties to heterochromatin. J Biol Chem. 2001;276:32282–32287
  240. Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-mediated methylation of Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007;39:232–236
  241. Fazzari MJ, Greally JM. Epigenomics: beyond CpG islands. Nat Rev Genet. 2004;5:446–455
  242. Ramsahoye BH, Biniszkiewicz D, Lyko F, Clark V, Bird AP, Jaenisch R. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci U S A. 2000;97:5237–5242
  243. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol. 2002;196:1–7
  244. Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 2001;20:2536–2544
  245. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300:455
  246. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science. 2003;300:489–492
  247. Richardson B. Impact of aging on DNA methylation. Ageing Res Rev. 2003;2:245–261
  248. Singhal RP, Mays-Hoopes LL, Eichhorn GL. DNA methylation in aging of mice. Mech Ageing Dev. 1987;41:199–210
  249. Herman JG, Baylin SB. Gene silencing in cancer in association with promotor hypermethylation. N Engl J Med. 2003;349:2042–2054
  250. Kitajima K, Tanaka M, Zheng J, et al. Redirecting differentiation of hematopoietic progenitors by a transcription factor, GATA-2. Blood. 2006;107:1857–1863
  251. Suzuki M, Yamada T, Kihara-Negishi F, et al. Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b. Oncogene. 2005;25:2477–2488
  252. Herman JG, Civin CI, Issa JPJ, Collector MI, Sharkis SJ, Baylin SB. Distinct pattern of p15INK4A and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837–841
  253. EL-Osta A. DNMT cooperativity—the developing links between methylation, chromatin structure and cancer. Bioessays. 2003;25:1071–1084
  254. Agrawal S, Hofmann WK, Tidow N, et al. The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood. 2007;109:3985–3905
  255. Costello JF, Frühwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nat Genet. 2000;24:132–138
  256. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921
  257. Lippman Z, Gendrel AV, Black M, et al. Role of transposable elements in heterochromatin and epigenetic control. Nature. 2004;430:471–476
  258. Kazazian HH. Mobile elements: driver of genome evolution. Science. 2004;303:1626–1632
  259. Capy P, Gasperi G, Biémont C, Bazin C. Stress and transposable elements: co-evolution or useful parasites?. Heredity. 2000;85:101–106
  260. Scholes DT, Kenny AE, Gamache ER, Mou Z, Curcio MJ. Activation of a LTR-retrotransposon by telomere erosion. Proc Natl Acad Sci U S A. 2003;100:15736–15741
  261. Han JS, Szak ST, Boeke JD. Transcriptional disruption by L1 retrotransposon and implications for mammalian transcriptomes. Nature. 2004;429:268–274
  262. Cheng C, Daigen M, Hirochika H. Epigenetic regulation of the rice retrotransposon Tos17. Mol Gen Genomics. 2006;276:378–390
  263. Liu ZL, Han FP, Tan M, et al. Activation of a rice endogenous retrotransposon Tos17 in tissue culture is accompanied by cytosine demethylation and causes heritable alteration in methylation pattern of flanking genomic regions. Theor Appl Genet. 2004;109:200–209
  264. Denne M, Sauter M, Armbruester V, Licht JD, Roemer K, Mueller-Lantzsch N. Physical and functional interactions of human endogenous retrovirus proteins Np9 and Rec with the promyelocytic leukemia zinc finger protein. J Virol. 2007;81:5607–5616
  265. Parseval de N, Heidmann T. Human endogenous retroviruses: from infectious elements to human genes. Cytogenet Genome Res. 2005;110:318–332
  266. Wang-Johanning F, Liu J, Rycaj K, et al. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer. 2006;120:81–90
  267. Lewitzky M, Yamanaka S. Reprogramming somatic cells towards pluripotency by defined factors. Curr Opin Biotechnol. 2007;18:467–473
  268. Nelson PN, Carnegie PR, Martin J, et al. Demystified human endogenous retroviruses. J Clin Pathol Mol Pathol. 2003;56:11–18
  269. Büscher K, Trefzer U, Hofmann M, Sterry W, Kurth R, Denner J. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res. 2005;65:4172–4180
  270. Griffiths DJ. Endogenous retroviruses in the human genome sequence. Genome Biol. 2001;2:1017.1–1017.5reviews
  271. Moyes D, Griffiths DJ, Venables PJ. Insertional polymorphisms: a new lease of life for endogenous retroviruses in human disease. Trends Genet. 2007;23:326–333
  272. Bannert N, Kurth R. Retroelements and the human genome: new perspectives on an old relation. Proc Natl Acad Sci U S A. 2004;101(Suppl 2):14572–14579
  273. Gifford R, Tristem M. The evolution, distribution and diversity of endogenous retroviruses. Virus Genes. 2003;26:3,291–3,315
  274. Prindull GA, Fibach E. Are postnatal hemangioblasts generated by dedifferentiation from committed hematopoietic stem cells?. Exp Hematol. 2007;35:691–701
  275. Perez-Pomares JM, Munoz-Chapuli E. Epithelial-mesenchymal transitions: a mesodermal cell strategy for evolutive innovation in metazoans. Anat Rec. 2002;268:343–351
  276. Duelli DM, Lazebnik YA. Primary cells suppress oncogene-dependent apoptosis. Nat Cell Biol. 2000;2:859–862
  277. Malumbres M, Pérez De Castro I, Hernández MI, Jiménez M, Corral T, Pellicer A. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15INK4b. Mol Cell Biol. 2000;20:2915–2925
  278. Lotem J, Sachs L. Epigenetics wins over genetics: induction of differentiation in tumor cells. Semin Cancer Biol. 2002;12:339–346
  279. Araki H, Yoshinaga K, Boccuni P, Zhao Y, Hoffman R, Mahmud N. Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulation potential. Blood. 2007;109:3570–3578
  280. Lavelle D, Vaitkus K, Hankewych M, Singh M, DeSimone J. Effect of 5-ara-2′-deoxycytidine (Dacogen) on covalent histone modifications of chromatin associated with the ε-, γ-, and β-globin promoters in Papio anubis. Exp Hematol. 2006;34:339–347
  281. Waggoner D. Mechanisms of disease: epigenesis. Semin Pediatr Neurol. 2007;14:7–14
  282. Huntly BJP, Gilliland DG. Summing up cancer stem cells. Nature. 2005;435:1169–1170
  283. Jones RJ, Matsui WH, Smith BD. Cancer stem cells: are we missing the target?. J Nat Cancer Inst. 2004;96:583–585
  284. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood. 2006;107:431–434

PII: S0301-472X(08)00374-3

doi: 10.1016/j.exphem.2008.07.009

Experimental Hematology
Volume 36, Issue 11 , Pages 1403-1416 , November 2008

Article Tools

* Image Usage & Resolution